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Abstract
Background: In recent years, research efforts exploring the possibility of using biomaterial nanoparticles for intravitreous
drug delivery has increased significantly. However, little is known about the effect of material properties on intravitreous
tissue responses.
Principal Findings: To find the answer, nanoparticles made of hyaluronic acid (HA), poly (l-lactic acid) (PLLA), polystyrene
(PS), and Poly N-isopropyl acrylamide (PNIPAM) were tested using intravitreous rabbit implantation model. Shortly after
implantation, we found that most of the implants accumulated in the trabecular meshwork area followed by clearance from
the vitreous. Interestingly, substantial reduction of intraocular pressure (IOP) was observed in eyes implanted with particles
made of PS, PNIPAM and PLLA, but not HA nanoparticles and buffered salt solution control. On the other hand, based on
histology, we found that the particle implantation had no influence on cornea, iris and even retina. Surprisingly, substantial
CD11b+ inflammatory cells were found to accumulate in the trabecular meshwork area in some animals. In addition, there
was a good relationship between recruited CD11b+ cells and IOP reduction.
Conclusions: Overall, the results reveal the potential influence of nanoparticle material properties on IOP reduction and
inflammatory responses in trabecular meshwork. Such interactions may be critical for the development of future ocular
nanodevices with improved safety and perhaps efficacy.
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Introduction
Posterior ocular diseases, including glaucoma, macular degen-
eration, uveal melanoma and retinoblastoma are often hard to be
treated due to ocular tissue barriers [1–3]. While topical
administration is effective in the treatment of anterior chamber
diseases, it is ineffective in the treatment of diseases afflicting the
posterior segments of the eye [2]. Major problems include washing
away of the drug by tears and the inefficient diffusion of drug from
the corneal side to the posterior [4,5]. Systemic injection does
deliver drugs to the posterior of the eye but is also associated with
non-specific accumulation of drug in other organs. In addition the
blood retinal barrier also hinders the diffusion of drug into the
posterior chamber [2]. In light of this information, intraocular
drug injections have gained in importance. However, although
they achieve therapeutic drug levels, they are associated with high
vitreal clearance which necessitates multiple injections. This in
turn leads to complications of endophthalmitis and retinal
detachment [2,3,6]. There is a need for the development of
alternative treatments for posterior ocular diseases.
Many therapeutic strategies have been developed in recent
years. One such method is the use of biomaterial drug delivery
devices either in the form of implants or as micro or nanoparticles
[2,7,8]. Despite of their ability to release therapeutic agents for a
prolonged period of time, ocular rod implants have been found to
be responsible for causing retinal detachment and endophthalmitis
[6]. With the expansion of nanotechnology in medicine, a wide
variety of nanoparticle drug releasing devices have been fabricated
and tested for their ability to treat a wide range of diseases [1,9–
12]. Many studies have been done to explore the possibility of
using polymeric micro and nanoparticles for anterior and posterior
chamber drug delivery [1,9–15]. Although microparticles have
better drug loading capacity than nanoparticles, the latter is
recognized as favorable drug carrier due to its low risk on
hampering normal vision [16,17]. Although different types of
nanoparticles have been investigated for their ability to target
different cells, tissues and to cure different ocular diseases [9–
12,14,15,18–22]. very limited studies have been done to
systematically evaluate the effect of material physical and chemical
properties on their ocular tissue and cell compatibility.
It is well established that the physical and chemical properties of
materials affect their cell and tissue compatibility [23–27]. We thus
assumed that nanoparticles made of different materials are likely to
cause different extents of acute tissue responses in the eye. To test
this hypothesis, nanoparticles made of different materials were
included in this study. Specifically, nanoparticles were made out of
degradable polymers like poly (l-lactic acid) (PLLA), hydrogels like
poly N-isopropyl acrylamide (PNIPAM), non-degradable materials
PLoS ONE | www.plosone.org 1 December 2011 | Volume 6 | Issue 12 | e28720like polystyrene (PS), and biological materials like hyaluronic acid
(HA). The ocular compatibility of these nanoparticles was
evaluated using rabbit intravitreous implantation model. After
implantation for different periods of time, we measured the
changes in intraocular pressure (IOP). At the end of the studies,
animals were sacrificed and ocular tissues were histologically
evaluated. The effect of material properties on the ocular tissue
responses was then determined to show that it can play a key role
in determining the fate of nanoparticles in the eye.
Methods
Ethics Statement
The animal use protocols (A06-028, A09-028) were reviewed
and approved by the Institutional Animal Care and Use
Committee of the University of Texas at Arlington.
Materials
N-Isopropylacrylamide was purchased from Polysciences.
Sodium acrylate (NaAc), N,N9-Methylene-bis-acrylamide (BIS)
and potassium persulfate (KPS) were purchased from Bio-Rad
(Hercules, CA, USA). Poly (L-lactic acid) (PLLA, MW
1.37610
6 kDa) was purchased from Birmingham Polymers
(Birmingham, AL, USA). N-(3 Dimethylaminopropyl)-N9-ethyl-
carbodiimide hydrochloride (EDAC), Fluorescein isothiocyanate
(FITC), Polystyrene and hyaluronic acid were purchased from
Sigma, St. Louis, USA. Balanced Salt Solution (BSS) was obtained
from Alcon Inc (Fort Worth, TX, USA).
Nanoparticle synthesis
Both poly N-isopropylacrylamide (PNIPAM) and PS nanopar-
ticles were synthesized based on established techniques [28,29,30–
32]. To study the distribution of the intravitreous injected
nanoparticles, some PNIPAM nanoparticles were conjugated with
FITC using carbodiimide chemistry [33,34]. HA nanoparticles
were synthesized as described earlier [35]. Briefly, acetone was
added in a weight ratio of 100:80 to a 0.5 wt% HA solution and
the HA/water/acetone mixture was stirred for 2 hours. EDAC
was added to the mixture in a weight ratio of 0.05:100 to form a
crosslinked mixture. This mixture was then stirred at 20 to 22uC
for approximately 24 hours after which acetone in a weight ratio
of approximately 60:100 was added to form the final mixture that
was stirred for 20 hours and dialyzed against distilled water to
form HA nanoparticles.
Animal implantation
Dutch rabbits (4–5 lb) were purchased from Myrtle’s Rabbitry
Inc (Thompsons Station, TN). All experimental procedures were
approved by the Institutional Animal Care and Use Committee
(IACUC) at the University of Texas at Arlington and carried out
under veterinary supervision. Prior to the procedures, animals
were sedated by subcutaneous injection of a 1:5 mixture of
100 mg/ml xylazine (Rompun; Miles Laboratories, Shawnee
Mission, KS) and 100 mg/ml Ketamine HCl (Ketaset; Bristol
laboratories. Syracuse, NY). One drop of topical anesthetic
Proparacaine HCl (0.5%; Alcon Laboratories, Fort Worth, TX)
was administered to each eye before injection. One hundred ml
(20 g/l) of each type of particle was injected in to intravitreal space
of the right eye via 30 gauge needle on a 1 ml tuberculin syringe.
The intravitreal space of the left eye was injected with 100 mlo f
balanced salt solution (BSS) and served as control. The points
where the intravitreal injections were made were approximately 2–
3 mm from the corneal limbus as suggested in early publications
[36,37]. All injections were performed by the same researcher to
avoid individual operational variations.
Intraocular pressure measurement
Intraocular pressure (IOP) has often been used as an indicator
for various ocular diseases [38,39]. The IOP was measured using a
calibrated pneumatonometer (Model 30 Classic; Mentor Co.,
Norwell, MA, U.S.A.) one day before and daily for 3 days after
nanoparticle injection as described earlier [40]. The results of the
IOP reading were taken in the confidence interval greater than or
equal to 95%. Measurements were taken at the same hour in order
to avoid circadian changes. The changes in IOP were calculated
by subtracting the IOPs at the end of 3 days from that before
particle injection.
Ocular imaging and histological Analyses
After intravitreous implantation of nanoparticles for different
periods of time (2 hrs, 4 hrs and 1 day), rabbits were euthanized
and eyes were recovered and frozen sectioned. To image
intravitreous distribution of nanoparticles, ocular tissue sections
from animals implanted with PNIPAM nanoparticles were
scanned using a Genepix Microarray analyzer (Molecular Devices,
Sunnyvale, CA). The fluorescence intensities in different areas of
the ocular tissues were analyzed and then compared. Furthermore,
some tissue sections were H&E stained and the extent of implant-
associated ocular tissue responses was quantified by measuring the
thickness of various ocular tissues like cornea, iris and retina using
a Leica microscope (Leica Microsystems, Wetzlar, GmbH)
equipped with a Nikon E500 Camera (8.4 V, 0.9 A, Nikon Corp.,
Japan). To assess the extent of acute inflammatory responses, some
tissue sections underwent immunohistological staining for
CD11b+ inflammatory cells in which images were captured with
a CCD camera (Retiga EXi, Qimaging, Surrey BC, Canada) and
cell densities were analyzed using NIH ImageJ program as
described in our previous publications [41,42].
Statistical Analyses
All results were expressed as mean 6 SD. All statistical
comparisons were made with BSS controls using t-tests. Differ-
ences were considered statistically significant at p,0.05 Linear
regression analyses was conducted with the Intraocular pressure
change represented by mm of Hg was used as the dependent
variable, while the CD11b+ cell numbers were the explanatory
variables.
Results
Changes in intraocular pressure after intravitreous
particle injection
Particles made of different materials were used in this
investigation (Table 1). These particles had diameter between
100–200 nm. Both PLLA and PS particles are hydrophobic while
HA and PNIPAM particles were hydrophilic. It should be noted
that PLLA and HA particles are biodegradable whereas PS and
PNIPAM particles are non-degradable. Following intravitreous
implantation, nanoparticle implants did not trigger apparent
adverse response or abnormality. Rather surprisingly, we found
that the intravitreous implantation of particles affected IOP
significantly. Specifically, the injection of PLLA, PS and PNIPAM
particles caused substantial reduction of IOP (Figure 1). On the
other hand, the injection of HA nanoparticles and BSS (as control)
had no effect on IOP. Such pressure changes lasted for less than 3
days. Although the cause of such particle implant-mediated IOP
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particle implants affects their acute ocular compatibility.
Distribution of intra-vitreous injected nanoparticles
To determine the potential interaction between injected
particles with ocular tissues, we first monitored the particle
distribution following intravitreous implantation using FITC-
labeled PNIPAM particles. As shown in the whole ocular section
images, we found that, at 2 hours, implanted particles were only
found in the posterior, but not anterior segment of eye. We also
found uniform fluorescence along the wall of the posterior
segments indicating the even spread of particles over the retinal
tissue (Figure 2A). Interestingly, we found that substantially more
particles accumulated in the trabecular meshwork area even at an
early time point – 2 hours. With increasing amount of time (4 and
24 hours) following implantation, we found that the particle-
associated fluorescence intensities reduced substantially in the
posterior chamber (Figure 2A and B). Interestingly, by 4 hours the
fluorescence intensity at the trabecular meshwork was significantly
higher than the rest of the eye and substantial fluorescent signals
were also found outside the ocular tissue nearby the trabecular
outflow region. Based on the fluorescent intensity measurements
and distribution, noticeably, most of the particles cleared from the
central portion of posterior chambers while majority of the
residual fluorescence intensity was seen in the area of trabecular
meshwork prior to clearance from the posterior cavities shortly
after 24 hours. Quantification of the distribution of fluorescent
particles throughout the ocular tissues further confirmed the
presence of particles in the trabecular meshwork area (Figure 2C).
These results suggest that the particle implants have little or no
contact with corneal and iris tissues. On the other hand, based on
the fluorescence distribution, it is likely that many posterior ocular
tissues, including retina and trabecular meshwork, were exposed to
particle implants.
Effect of material properties on ocular tissue responses
To assess the potential ocular compatibility of particle implants,
various ocular tissues in both anterior and posterior segments were
histologically analyzed. As expected, we found that the intravitreous
injection of particles have no apparent influence on the anatomical
structure of cornea (Figure 3A) and iris (Figure 3B) tissue based on
morphological assessment of tissue thickness (Figures 3C & D).
Although PNIPAM particle-implanted animals showed the lowest
corneal and iris tissue thickness, the differences were not statistically
Table 1. Physical properties of nanoparticles used for intravitreous implantation.
Material Type Wettability Degradable Size nm
Buffered Salt Solution Solution Aqueous solution NA NA
Poly (l-lactic) Acid Polymeric Hydrophobic Yes 143
Polystyrene Polymeric Hydrophobic No 100
Hyaluronic Acid Polymeric Hydrophilic Yes 200
Poly N-isopropyl acrylamide Polymeric Hydrogel Hydrophilic No 100
doi:10.1371/journal.pone.0028720.t001
Figure 1. Assessment of mean intraocular pressure variations after administration of particles made of poly-L lactic acid (PLLA),
polystyrene (PS), hyaluronic acid (HA), and poly N-isopropyl acrylamide (PNIPAM) and Balanced Salt Solution (BSS) in the vitreous.
Data are mean 6 standard deviation. Significance of PLLA, PS, HA, PNIPAM vs. BSS control; * p,0.05.
doi:10.1371/journal.pone.0028720.g001
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control. Rather surprisingly, despite of the apparent interaction
between particles and retinal tissue, we found that particle implants
have no influence on the anatomical structure and thickness of
retinal tissues (Figure 4A & B). How the injection of particle
implants reduced IOP, was yet to be answered.
Figure 2. Distribution of FITC-labeled PNIPAM nanoparticles after intravitreous administration over a day. Localization of fluorescence
in the posterior segments of the eye at various time points (2, 4 and 24 hours) was observed (A) and quantified (B). Quantification of the normalized
fluorescence intensity at various locations (TB: Trabecular Meshwork; RA: Retina; ON: Optic Nerve) at various time points (C).
doi:10.1371/journal.pone.0028720.g002
Figure 3. Histological assessment of corneal and iris tissue after intravitreous implantation. The representative H&E images of the cornea
(A) and iris (B) tissue were shown here. Based on H&E staining images, the influence of particle property on the thickness of the corneal (C) and iris (D)
thickness were quantified. Data are mean 6 standard deviation. Significance of PLLA, PS, HA, PNIPAM vs. BSS control; * p,0.05.
doi:10.1371/journal.pone.0028720.g003
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meshwork tissue
It is well established that trabecular meshwork is responsible
for controlling IOP [43], and increased inflammatory responses
in trabecular meshwork have been shown to cause IOP reduction
in human patients [44]. Since our results have shown that
substantial portion of the injected particles accumulated in
trabecular meshwork prior to clearance from the posterior
chamber, we assumed that some particle implants may trigger
such inflammatory responses in trabecular meshwork tissue and
then lead to the reduction of IOP. To test this hypothesis,
immunohistological analysis of ocular tissues was performed by
examining the presence or absence of CD11b+ inflammatory
cells in the trabecular meshwork area around the ciliary body.
Indeed, we found that both PS and PNIPAM particle groups
were associated with very high CD11b+ cell accumulation
(labeled green) (Figure 5A) while PLLA particles prompt less
(,20%) CD11b+ cell accumulation as compared with PS and
PNIPAM particle groups. It should be noted that there were
almost no CD11b+ cells in the HA nanoparticle group as well as
BSS control. The average CD11b+ cell numbers from numerous
sections were quantified to substantiate the visual observations
(Figure 5B). To investigate the relationship between inflammatory
cell accumulation and IOP reduction, then numbers of CD11b+
cells from different sample groups were then correlated with
averages of IOP from respective sample groups. As expected,
there was a very good relationship between CD11b+ cell
numbers found in the trabecular meshwork tissues and overall
IOP reduction (Figure 5C).
Discussion
Drug delivery to the back of the eye, especially the posterior
segments, is a key research area and important considering
numerous ocular diseases that afflict that region. However, most
drug administration techniques like topical administration or even
implantable rods have their own drawbacks as has been reviewed
in our earlier publication [3]. Administration of drug directly into
the vitreous is also associated with a lot of problems; clearance of
the drug being one of the main drawbacks [2,45]. In light of this
fact, nanotechnology has come to the forefront of ocular drug
delivery and as such, understanding ocular tissue response to
implanted nano-biomaterials is of paramount significance
[2,3,8,46]. Our selection of materials to synthesize various
nanoparticles was based on the following facts. First, a vast
majority of drug releasing nanodevices are made out of FDA
approved polymers like PLLA and PLGA and are usually in the
Figure 4. Evaluation of retinal tissue morphology following intravitreal injection. Representative H&E stained retinal tissues were shown
here (A). The thickness of the retinal tissue was also calculated and then compared (B). Data are mean 6 standard deviation. Significance of PLLA, PS,
HA, PNIPAM vs. BSS control; * p,0.05.
doi:10.1371/journal.pone.0028720.g004
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shown that particles in the range of 20 nm to 200 nm have the
highest affinity to tissue [13,48]. Second, hydrogels like PNIPAM
have been extensively researched for drug delivery applications
[14,49–51]. Thirdly, HA is a major component of the vitreous and
as such, their presence in the eye should be tolerable. HA makes
up a sizeable proportion in the retinal pigment epithelium and
interphotoreceptor matrix [52]. Considering this information, we
selected nanoparticles made out of PLLA, PS, HA and PNIPAM
in the size range of 100 to 200 nm.
It is well established that material properties trigger different
extent of soft tissue responses [25,53]. We thus assumed that
material properties would exert some influence on ocular tissue
reactions. Very few studies have been done to assess the effect of
material properties on ocular compatibility of particles. Neverthe-
less, studies have found that PLLA and PLGA nanoparticles can
be used for delivery of high molecular weight drugs to the retina
[54], and poly (e-caprolactone) is well tolerated by retinal tissue for
at least 4 weeks [55]. Non-toxic chitosan and hyaluronic acid have
been found to be good drug carriers [56,57], and carbodiimide
crosslinked hyaluronic acid has been shown to have good ocular
compatibility in the anterior chamber [58]. PNIPAM hydrogel
grafted with chitosan has also been applied as a thermally
responsive ophthalmic drug delivery device [51]. Also most of the
studies until now have mainly focused on visual signs of
inflammation to suggest lack of biocompatibility.
To determine the ocular tissue responses to particle implants, we
first measuredthe IOP changes followingintravitreous implantation
of particle. The fluctuation of IOP indicates the balance between
production and drainage of aqueous humor and hence it was
measured to determinetheimpact ofvariousnanoparticleinjections
on aqueous humor drainage [43,59]. In addition, it has been
documented that ocular inflammation strongly influences the IOP
[60–63]. Diseases like glaucoma have been shown to increase IOP
while inflammatory conditions produced by anterior uveitis and
iritis were found to reduce IOP [44,64–67]. Substantial studies in
glaucoma research have focused on using various pharmacological
approaches to reduce IOP for prolonged period of time [64,68].
Interestingly, our studies have found that the intravitreous
implantation of particles prompted different extent of IOP
reduction. Specifically, we found that PNIPAM and PS particles
triggered the maximum reduction in IOP, while PLLA particles
caused a rather mild reduction in IOP. Most interestingly, our
results show that the implantation of HA particles trigger minimal
or no IOP reduction. In fact, many studies have shown that HA
particles have superb tissue compatibility in other body parts
Figure 5. The accumulation of CD11b+ inflammatory cells in the trabecular meshwork. The representative immunohistochemically
stained images showed the accumulation of CD11b+ inflammatory cells (labeled green; DAPI staining to locate cell nucleus) in the trabecular
meshwork following particle injection (A). The extent of CD11b+ cell accumulation in the trabecular meshwork was quantified (B). Data are mean 6
standard deviation. Significance of PLLA, PS, HA, PNIPAM vs. BSS control; * p,0.05 Correlation between CD11b+ inflammatory cells and average IOP
changes in different test groups was also determined (C).
doi:10.1371/journal.pone.0028720.g005
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evaluating the biocompatibility of intravitreal hyaluronic acid
implants found that there were no evident signs of inflammation
following implantation [71]. These results suggest that HA particles
are good nanocarriers for posterior drug delivery.
To find the cause for particle implant-mediated IOP reduction,
we first observed the distribution of the implants following
intravitreous implantation. Although extensive research efforts
have been placed on the development of nanocarriers for anterior
and posterior ocular drug delivery, little has been done to study the
fate of particle implants following injection. Briefly, these studies
have revealed that nano and microparticles can reach the
intraocular tissues when administered systemically or through
periocular administration routes [48,72]. However, it has also
been reported that systemic administration of drug requires high
doses to offset loss due to non-specific targeting and systemic side
effects [73]. Our studies revealed that, rather surprisingly, majority
of the particle implants injected intravitreally, only stay in the
posterior segments for a very short period of time (,24 hours).
These results support that that, differing from common assump-
tion that intravitreous administration will lead to better distribu-
tion, humor flow actively pushed particle implants out of the
posterior. In addition, particle implants may reach retinal tissues
shortly after intravitreous injection. Although the fate of the
particles is yet to be determined, it is plausible that most of the
particle implants exit the posterior chamber via the trabecular
meshwork based on the fluorescent intensity distribution. This
observation is supported by several earlier observations that
particles and drugs may leave vitreous compartment via the
trabecular meshwork [43,74].
Particle implants have been shown to trigger immune reactions
in the surrounding tissues [23,25], and it is likely that similar
particle-mediated tissue responses are also found in ocular tissues.
To the best of our knowledge, very few studies have been done in
this regard. A few studies have tested poly(ortho esters) following
intravitreal injection and found no evident signs of inflammatory
reaction up to 3 months [75]. Studies involving PLGA
microspheres [76], and porous silicon microparticles [77], found
that they were well tolerated with no clinical signs of inflammation
based on visual examination even four days to four months after
implantation. A recent study has also evaluated the ocular
compatibility of gluteraldehyde crosslinked and EDAC crosslinked
hyaluronic acid implants in the anterior chamber and found that
EDAC crosslinked implants were more compatible [58]. However,
it is mostly unclear whether the intravitreous implantation of
particles would trigger immune reactions in different ocular
tissues, including cornea, iris, retina and trabecular meshwork. To
our surprise, we found that all the tested particle implants had no
significant influence on the morphology and anatomical structure
of cornea, iris, retina tissue despite of apparent short term
accumulation of particle implants in nearby retinal tissue.
It is well established that trabecular meshwork and surrounding
ciliary body is responsible for maintaining the IOP [78–81]. To
search for the cause of IOP changes following particle implanta-
tion, we examined the tissue responses in the trabecular
meshwork. It should be noted that the potential influence of
intravitreous particle implants on trabecular meshwork function
have not been evaluated prior to this work. The trabecular
meshwork, upon examination showed signs of apparent acute
inflammatory responses with accumulation of CD11b+ cells in
some groups of animals, especially animals with PS particle or
PNIPAM implants. Mild accumulation of CD11b+ cells in
trabecular meshwork was also found in animals implanted with
PLLA particles. Interestingly, no CD11b+ cells were found in the
tissues isolated from animals implanted with either HA particles or
BSS controls. Equally importantly, we found a good relationship
between the numbers of CD11b+ cells in trabecular meshwork
and the average IOP reduction in different groups of implants.
These results suggest that particle implant-associated inflammato-
ry responses in trabecular meshwork are responsible for IOP
reduction and are supported by many earlier works in which
inflammatory responses inside trabecular meshwork have been
linked to the reduction of IOP [44,65,82].
The results from this study have emphasized the fact that IOP
should be measured as part of the evaluation of tissue
compatibility of ocular implants, specifically in the case of
nanoparticle and microparticle implants. Furthermore, the
‘‘normal’’ anatomical structure of retinal, corneal and iris tissue
does not guarantee the safety of ocular particle implants. Rather,
the histological evaluation of inflammatory responses in trabecular
meshwork should be done as an indicator of ocular compatibility
of intravitreous implants. Finally, further studies are needed to
investigate the influence of material physical and chemical
properties on IOP changes and on trabecular tissue responses.
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